Published in Cancer Weekly, March 14th, 2006
The trial, which is ongoing at Georgetown University and the University of Alabama, is designed to determine the safety and tolerability of RX-0201 in patients with cancer. The trial protocol calls for patients to undergo two cycles of 2 weeks on the drug and 1 week off. At 192 mg/M2,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.